Fidelity Investments
DRMA icon

Fidelity Investments’s Dermata Therapeutics DRMA Stock Holding History

Fidelity Investments’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed -$5K – 5397
2022
Q3 		$5K Buy
+4
New +$6.24K ﹤0.01% 4302

Other funds holding DRMA

RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SCA
Sage Capital Advisors Sioux Falls, South Dakota $482M AUM 34.73% 1-Year Est. Return
HA
HC Advisors Sandy Springs, Georgia $165M AUM 20.85% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Fidelity Investments's DRMA Position: Q4 2022 in Review

Fidelity Investments sold out of Dermata Therapeutics (DRMA) in Q4 2022, closing a stake of 4 shares — an estimated $5K sold.

Fidelity Investments first reported a position in DRMA in Q3 2022 and held it in 1 quarter. The position peaked at $5K in Q3 2022. 10 funds tracked by Wall St. Rank hold DRMA as of Q4 2022.

  • Fidelity Investments reported no remaining Dermata Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Fidelity Investments sold 4 Dermata Therapeutics shares in Q4 2022, an estimated $5K.
  • Fidelity Investments first reported a position in Dermata Therapeutics in Q3 2022 and held it in 1 quarter.
  • Fidelity Investments's Dermata Therapeutics position peaked at $5K in Q3 2022.
  • 10 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q4 2022.

Based on Fidelity Investments's 13F filing for Q4 2022, filed 13 Feb 2023.